Prince Pharmaceutical Co., Ltd.
Prince Pharmaceutical Co., Ltd. manufactures and sells vitamin B1 active pharmaceutical ingredients (APIs) in Taiwan, Japan, Korea, and internationally. The company also offers health food and medicines; vitamin c tablets, vitamin b complex tablets, natto and rhodiola extract capsules, probiotic sachets, and plant extract capsules; and API products comprising felbinac, aldioxa, tulobuterol, ufena… Read more
Prince Pharmaceutical Co., Ltd. (6935) - Net Assets
Latest net assets as of June 2025: NT$740.69 Million TWD
Based on the latest financial reports, Prince Pharmaceutical Co., Ltd. (6935) has net assets worth NT$740.69 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.36 Billion) and total liabilities (NT$618.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$740.69 Million |
| % of Total Assets | 54.51% |
| Annual Growth Rate | 3.11% |
| 5-Year Change | 18.22% |
| 10-Year Change | N/A |
| Growth Volatility | 8.77 |
Prince Pharmaceutical Co., Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how Prince Pharmaceutical Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Prince Pharmaceutical Co., Ltd. (2019–2024)
The table below shows the annual net assets of Prince Pharmaceutical Co., Ltd. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$722.06 Million | -6.77% |
| 2023-12-31 | NT$774.47 Million | +17.63% |
| 2022-12-31 | NT$658.38 Million | +9.21% |
| 2021-12-31 | NT$602.87 Million | -1.29% |
| 2020-12-31 | NT$610.77 Million | -1.43% |
| 2019-12-31 | NT$619.62 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Prince Pharmaceutical Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 159.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$366.05 Million | 50.70% |
| Other Comprehensive Income | NT$50.25 Million | 6.96% |
| Other Components | NT$325.56 Million | 45.09% |
| Total Equity | NT$722.06 Million | 100.00% |
Prince Pharmaceutical Co., Ltd. Competitors by Market Cap
The table below lists competitors of Prince Pharmaceutical Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TWL Holdings Bhd
KLSE:7079
|
$10.79 Million |
|
Replenish Nutrients Holding Corp.
F:7KE
|
$10.79 Million |
|
Peace & Living PCL
BK:PEACE
|
$10.79 Million |
|
Alton Sports Co.Ltd
KQ:123750
|
$10.79 Million |
|
TVI Pacific Inc
PINK:TVIPF
|
$10.78 Million |
|
Barrister Energy LLC
PINK:CJAX
|
$10.78 Million |
|
Choice Development Inc
TW:9929
|
$10.77 Million |
|
Inswave Systems Co., Ltd.
KQ:450520
|
$10.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Prince Pharmaceutical Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 774,466,000 to 722,060,000, a change of -52,406,000 (-6.8%).
- Net loss of 53,542,000 reduced equity.
- Dividend payments of 9,151,000 reduced retained earnings.
- Other comprehensive income increased equity by 50,247,000.
- Other factors decreased equity by 39,960,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-53.54 Million | -7.42% |
| Dividends Paid | NT$9.15 Million | -1.27% |
| Other Comprehensive Income | NT$50.25 Million | +6.96% |
| Other Changes | NT$-39.96 Million | -5.53% |
| Total Change | NT$- | -6.77% |
Book Value vs Market Value Analysis
This analysis compares Prince Pharmaceutical Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.41x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$19.33 | NT$27.90 | x |
| 2020-12-31 | NT$18.67 | NT$27.90 | x |
| 2021-12-31 | NT$18.16 | NT$27.90 | x |
| 2022-12-31 | NT$19.75 | NT$27.90 | x |
| 2023-12-31 | NT$21.25 | NT$27.90 | x |
| 2024-12-31 | NT$19.75 | NT$27.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Prince Pharmaceutical Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7.76%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 1.87x
- Recent ROE (-7.42%) is below the historical average (-0.75%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.22x | 1.87x | NT$-61.95 Million |
| 2020 | -5.53% | -11.43% | 0.24x | 1.99x | NT$-94.88 Million |
| 2021 | -1.38% | -1.88% | 0.34x | 2.14x | NT$-68.59 Million |
| 2022 | 7.83% | 7.24% | 0.55x | 1.98x | NT$-14.28 Million |
| 2023 | 1.98% | 2.03% | 0.53x | 1.82x | NT$-62.14 Million |
| 2024 | -7.42% | -7.76% | 0.51x | 1.87x | NT$-125.75 Million |
Industry Comparison
This section compares Prince Pharmaceutical Co., Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,528,453,600
- Average return on equity (ROE) among peers: 3.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Prince Pharmaceutical Co., Ltd. (6935) | NT$740.69 Million | 0.00% | 0.83x | $10.78 Million |
| Grape King Bio Ltd (1707) | $11.79 Billion | 12.28% | 0.30x | $413.97 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $8.14 Billion | 10.26% | 0.37x | $160.24 Million |
| Maywufa Co Ltd (1731) | $2.11 Billion | 8.22% | 0.51x | $41.33 Million |
| Allied Biotech Corporation (1780) | $1.17 Billion | 8.33% | 0.78x | $47.92 Million |
| ScinoPharm Taiwan Ltd (1789) | $9.38 Billion | 5.16% | 0.21x | $180.77 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $24.30 Million |
| Easywell Biomedicals Inc. (1799) | $696.90 Million | -39.00% | 0.68x | $62.14 Million |
| LIWANLI Innovation Co Ltd (3054) | $799.59 Million | 4.48% | 0.55x | $49.55 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $292.12 Million |
| TTY Biopharm Co Ltd (4105) | $6.11 Billion | 22.00% | 0.56x | $486.74 Million |